Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Evolus from “Hold” to “Buy,” while the broader analyst consensus is “Moderate Buy” with an average price target of $14.50.
• Evolus shares rose 2.4% to open at $7.59, near their 12-month high of $7.95; the stock’s 50-day and 200-day moving averages are $6.50 and $5.54, respectively.
• Institutional ownership stands at 90.69%, with several hedge funds and investment managers recently initiating or increasing positions in the medical aesthetics company.

Evolus (NASDAQ:EOLS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

Several other analysts also recently issued reports on the company. BTIG Research restated a "buy" rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings upgraded Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, June 15th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Evolus has a consensus rating of "Moderate Buy" and an average target price of $14.50.

Evolus Stock Up 2.4%

Shares of NASDAQ:EOLS opened at $7.59 on Friday. Evolus has a 12-month low of $3.86 and a 12-month high of $7.95. The business has a 50 day moving average of $6.50 and a 200-day moving average of $5.54. The stock has a market cap of $501.32 million, a PE ratio of -14.60 and a beta of 1.35.

Institutional Investors Weigh In On Evolus

A number of hedge funds and other institutional investors have recently made changes to their positions in EOLS. Larson Financial Group LLC grew its position in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock worth $33,000 after buying an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Evolus in the 4th quarter valued at $34,000. Wexford Capital LP acquired a new position in Evolus in the 3rd quarter valued at $37,000. Aquatic Capital Management LLC bought a new stake in shares of Evolus during the 3rd quarter valued at $48,000. Finally, State of Wyoming bought a new stake in shares of Evolus during the 4th quarter valued at $63,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source